ArticleMedComm2025
Prognostic Value of Coronary Angiography-Derived Index of Microvascular Resistance in Patients With Hypertrophic Cardiomyopathy.
Article in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Validity of angiography-derived microvascular resistance in hypertrophic cardiomyopathy: a head-to-head comparison with pressure-wire IMR.The international journal of cardiovascular imaging · 2026Article
- Machine learning-based risk stratification identifies heart failure with preserved ejection fraction as an independent predictor of adverse outcomes in hypertrophic cardiomyopathy.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Assessing coronary microcirculation is crucial in the progression of hypertrophic cardiomyopathy (HCM), but it's often inadequate in clinical practice. This study investigates the role of coronary microcirculation, assessed via angiography-derived index of microvascular resistance (angio-IMR), in predicting clinical outcomes in HCM patients. We retrospectively measured angio-IMR in 422 HCM patients across two sites. The primary endpoint was major advance cardiovascular event (MACE), including cardiovascular death, heart failure readmission, life-threatening ventricular arrhythmias, septal reduction therapy or new-onset stroke. Over a mean follow-up of 43 ± 23 months, 63 patients (14.93%) experienced MACE. The mean angio-IMR value for the left anterior descending artery (LAD) was 22 ± 8. Using maximally selected log-rank statistic, 123 patients were stratified into the high LAD angio-IMR group, indicating microvascular dysfunction. Patients with LAD angio-IMR > 25 exhibited a higher incidence of MACE than those with LAD angio-IMR ≤ 25 (25.4% vs. 13.3%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.